Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Business Wire•21/10/2026•13:10 ET
0
Key Highlights
- ➤Molgramostim cut mean A–aDO₂ by 12.7 mmHg at Week 24 versus 0.3 mmHg for placebo
- ➤Molgramostim reduced mean chest CT ground-glass opacity score by 4.9 points
- ➤Molgramostim improved respiratory quality-of-life activity scores by 11.1 points
- ➤Analysis included only 8 once-daily molgramostim and 3 placebo patients
- ➤Findings were descriptive, exploratory, and hypothesis-generating due to small sample size
Expert Statements
Bruce C. Trapnell, M.D., Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine
“In this analysis, patients with relatively preserved diffusing capacity enrolled in IMPALA still showed impaired gas transfer, substantial surfactant burden, and reduced quality of life at baseline”
Bruce C. Trapnell, M.D., Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine
“Daily molgramostim was associated with improvements in each of these measures.”
Bruce C. Trapnell, M.D., Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine
“While exploratory, these findings, together with the Phase 3 IMPALA-2 results, support the potential of molgramostim, if approved, to benefit patients with aPAP across the spectrum of disease severity.”
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
-- Post-Hoc Analysis of the Phase 2/3 IMPALA Clinical Trial Presented in a Poster Presentation at the CHEST 2026 Annual Meeting --
Get started
Create a free account to read the full story.